补阳还五汤联合瑞舒伐他汀治疗急性脑梗死的临床疗效及对神经因子、脑血流动力学指标的影响OA
Clinical efficacy of Buyang Huanwu decoction combined with rosuvastatin in the treatment of acute cerebral infarction and its effect on neurological factor and cerebral hemodynamics
目的 探讨补阳还五汤联合瑞舒伐他汀治疗急性脑梗死(ACI)的临床疗效及对神经因子、脑血流动力学指标的影响.方法 选取2022年1月至2024年3月广安门医院保定医院收治的100例 ACI患者作为研究对象,按治疗方案分为常规组(52例)和联合组(48例).常规组给予瑞舒伐他汀治疗,联合组在常规组的基础上联合补阳还五汤治疗.比较2组患者的临床疗效;比较2组患者治疗前后神经因子[神经生长因子(NGF)、神经元特异性烯醇化酶(NSE)、脑源性神经营养因子(BDNF)]、脑血流动力学指标[脑血容量(CBV)、脑血流量(CBF)及平均通过时间(MTT)]、中医证候(言语謇涩或不语、偏身麻木、头晕目眩)积分及总分、美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数评分.结果 联合组总有效率为91.67%,高于常规组的76.92%,差异有统计学意义(P<0.05).2组治疗后Barthel指数评分、CBF、CBV及 NGF、BDNF水平均高于治疗前,且联合组治疗后Barthel指数评分、CBF、CBV及 NGF、BDNF水平均高于常规组,差异均有统计学意义(P<0.05).2组治疗后中医证候(言语謇涩或不语、偏身麻木、头晕目眩)积分及总分、NIHSS评分及 NSE水平均低于治疗前,MTT均短于治疗前,且联合组治疗后中医证候(言语謇涩或不语、偏身麻木、头晕目眩)积分及总分、NIHSS评分、NSE 水平均低于常规组,MTT 短于常规组,差异均有统计学意义(P<0.05).结论 在瑞舒伐他汀的基础上联合补阳还五汤治疗ACI,其临床疗效优于单用瑞舒伐他汀,并且能更有效地改善患者神经功能缺损、日常生活能力及脑血流灌注.
Objective To investigate the clinical efficacy of Buyang Huanwu decoction combined with rosu-vastatin in the treatment of acute cerebral infarction(ACI)and its effect on neurological factor and cerebral hemodynamic indexes.Methods A total of 100 patients with ACI admitted to Baoding Hospital of Guang'an-men Hospital from January 2022 to March 2024 were selected as the research objects,and they were divided into the conventional group(52 cases)and the combined group(48 cases)according to the different treatment plan.The conventional group was treated with rosuvastatin,and the combined group was treated with Buyang Huanwu decoction on the basis of the conventional group.The clinical efficacy of the two groups was com-pared.The neurological factors[nerve growth factor(NGF),neuron-specific enolase(NSE),brain-derived neurotrophic factor(BDNF)],cerebral hemodynamic indexes[cerebral blood volume(CBV),cerebral blood flow(CBF),and mean transit time(MTT)],and TCM syndromes(Speech Jian astringent or no language,partial body numbness,dizziness)and total score,National Institutes of Health Stroke Scale(NIHSS)score and Barthel index scorebefore and after treatment were compared between the two groups.Results The total effective rate of the combined group was 91.67%,which was higher than 76.92%of the conventional group,and the difference was statistically significant(P<0.05).After treatment,the Barthel index score,CBF,CBV,NGF,BDNF levels of the two groups were higher than those before treatment,and the Barthel index score,CBF,CBV,NGF,BDNF levels of the combined group were higher than those of the conventional group,and the differences were statistically significant(P<0.05).After treatment,the TCM syndrome score and to-tal score,NIHSS score and NSE level of the two groups were lower than those before treatment,MTT was shorter than that before treatment,and the TCM syndrome score and total score,NIHSS score and NSE level of the combined group were lower than those of the conventional group after treatment.MTT was shorter than that of the conventional group,and the differences were statistically significant(P<0.05).Conclusion The clinical efficacy of Buyang Huanwu decoction combined with rosuvastatin in the treatment of ACI is better than that of rosuvastatin alone,and it can more effectively improve the neurological deficit,daily living ability and cerebral blood perfusion of patients.
王延惠;张茜;刘泽芳;翟晓莹;李卫娜;魏萌萌
广安门医院保定医院药剂科,河北 保定 071023广安门医院保定医院药剂科,河北 保定 071023广安门医院保定医院药剂科,河北 保定 071023广安门医院保定医院药剂科,河北 保定 071023广安门医院保定医院药剂科,河北 保定 071023河北省保定市第二中心医院神经内科,河北 保定 072750
医药卫生
补阳还五汤瑞舒伐他汀急性脑梗死脑血流动力学指标神经功能临床疗效
Buyang Huanwu decoctionrosuvastatinacute cerebral infarctioncerebral hemody-namic indexneurological functionclinical efficacy
《检验医学与临床》 2026 (7)
917-922,6
河北省保定市科技计划项目(2241ZF200).
评论